VIB Vermögen Gelecekteki Büyüme

Future kriter kontrolleri 0/6

VIB Vermögen's earnings are forecast to decline at 19.3% per annum while its annual revenue is expected to grow at 2.8% per year. EPS is expected to decline by 19.2% per annum. Return on equity is forecast to be 6.7% in 3 years.

Anahtar bilgiler

-19.3%

Kazanç büyüme oranı

-19.2%

EPS büyüme oranı

Real Estate kazanç büyümesi93.1%
Gelir büyüme oranı2.8%
Gelecekteki özkaynak getirisi6.7%
Analist kapsamı

Low

Son güncelleme22 Aug 2024

Gelecekteki son büyüme güncellemeleri

VIB Vermögen AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Feb 18
VIB Vermögen AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Recent updates

Should You Think About Buying VIB Vermögen AG (ETR:VIH1) Now?

Oct 11
Should You Think About Buying VIB Vermögen AG (ETR:VIH1) Now?

VIB Vermögen AG (ETR:VIH1) Shares Fly 26% But Investors Aren't Buying For Growth

Sep 20
VIB Vermögen AG (ETR:VIH1) Shares Fly 26% But Investors Aren't Buying For Growth

Concerns Surrounding VIB Vermögen's (ETR:VIH1) Performance

May 08
Concerns Surrounding VIB Vermögen's (ETR:VIH1) Performance

When Should You Buy VIB Vermögen AG (ETR:VIH1)?

Dec 20
When Should You Buy VIB Vermögen AG (ETR:VIH1)?

Is VIB Vermögen (ETR:VIH1) Using Too Much Debt?

Jun 21
Is VIB Vermögen (ETR:VIH1) Using Too Much Debt?

Is Now The Time To Look At Buying VIB Vermögen AG (ETR:VIH1)?

May 30
Is Now The Time To Look At Buying VIB Vermögen AG (ETR:VIH1)?

VIB Vermögen AG (ETR:VIH1) Shares Could Be 43% Below Their Intrinsic Value Estimate

Mar 29
VIB Vermögen AG (ETR:VIH1) Shares Could Be 43% Below Their Intrinsic Value Estimate

VIB Vermögen AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Feb 18
VIB Vermögen AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Is It Too Late To Consider Buying VIB Vermögen AG (ETR:VIH1)?

Feb 11
Is It Too Late To Consider Buying VIB Vermögen AG (ETR:VIH1)?

Is It Too Late To Consider Buying VIB Vermögen AG (ETR:VIH1)?

Sep 06
Is It Too Late To Consider Buying VIB Vermögen AG (ETR:VIH1)?

Is VIB Vermögen (ETR:VIH1) A Risky Investment?

Oct 15
Is VIB Vermögen (ETR:VIH1) A Risky Investment?

VIB Vermögen (ETR:VIH1) Has Compensated Shareholders With A Respectable 100% Return On Their Investment

Mar 11
VIB Vermögen (ETR:VIH1) Has Compensated Shareholders With A Respectable 100% Return On Their Investment

A Closer Look At VIB Vermögen AG's (ETR:VIH1) Impressive ROE

Feb 18
A Closer Look At VIB Vermögen AG's (ETR:VIH1) Impressive ROE

You Have To Love VIB Vermögen AG's (ETR:VIH1) Dividend

Jan 19
You Have To Love VIB Vermögen AG's (ETR:VIH1) Dividend

Here's What VIB Vermögen AG's (ETR:VIH1) Shareholder Ownership Structure Looks Like

Dec 25
Here's What VIB Vermögen AG's (ETR:VIH1) Shareholder Ownership Structure Looks Like

Shareholders Of VIB Vermögen (ETR:VIH1) Must Be Happy With Their 94% Return

Dec 06
Shareholders Of VIB Vermögen (ETR:VIH1) Must Be Happy With Their 94% Return

A Closer Look At VIB Vermögen AG's (ETR:VIH1) Impressive ROE

Nov 18
A Closer Look At VIB Vermögen AG's (ETR:VIH1) Impressive ROE

Kazanç ve Gelir Büyüme Tahminleri

XTRA:VIH1 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (EUR Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/20261014970951
12/31/20259242111971
12/31/20248538151041
6/30/202498876868N/A
3/31/20241001087272N/A
12/31/20231031307575N/A
9/30/20231051077373N/A
6/30/2023108847171N/A
3/31/202312876N/AN/AN/A
12/31/2022128546868N/A
9/30/202212641N/AN/AN/A
6/30/2022126497474N/A
3/31/2022106143N/AN/AN/A
12/31/2021102307575N/A
9/30/202110154N/AN/AN/A
6/30/202198536971N/A
3/31/20219671N/AN/AN/A
12/31/202094666465N/A
9/30/20209471N/AN/AN/A
6/30/202093676464N/A
3/31/20209264N/AN/AN/A
12/31/201991636969N/A
9/30/20199058N/AN/AN/A
6/30/201989606767N/A
3/31/20198859N/AN/AN/A
12/31/201887586161N/A
9/30/20188658N/AN/AN/A
6/30/201885536161N/A
3/31/20188551N/AN/AN/A
12/31/20178452N/A59N/A
9/30/20178349N/AN/AN/A
6/30/20178250N/A57N/A
3/31/20178150N/AN/AN/A
12/31/20168047N/A58N/A
9/30/20167943N/AN/AN/A
6/30/20167844N/A56N/A
3/31/20167740N/AN/AN/A
12/31/20157540N/A54N/A
9/30/20157337N/AN/AN/A
6/30/20157232N/AN/AN/A
3/31/20157132N/AN/AN/A
12/31/20147031N/A48N/A
9/30/20146929N/AN/AN/A
6/30/20146828N/AN/AN/A
3/31/20146627N/AN/AN/A
12/31/20136527N/A48N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: VIH1's earnings are forecast to decline over the next 3 years (-19.3% per year).

Kazançlar ve Piyasa: VIH1's earnings are forecast to decline over the next 3 years (-19.3% per year).

Yüksek Büyüme Kazançları: VIH1's earnings are forecast to decline over the next 3 years.

Gelir ve Pazar: VIH1's revenue (2.8% per year) is forecast to grow slower than the German market (5.5% per year).

Yüksek Büyüme Geliri: VIH1's revenue (2.8% per year) is forecast to grow slower than 20% per year.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: VIH1's Return on Equity is forecast to be low in 3 years time (6.7%).


Büyüyen şirketleri keşfedin